<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is characterized by the presence of high titers of anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta(2)GPI) antibodies, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> associated with thromboembolic phenomena, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and recurrent fetal loss </plain></SENT>
<SENT sid="1" pm="."><plain>Single-chain Fv (scFv) were prepared from four anti-beta(2)GPI mAb, CAM, CAL, CAR and 2C4C2, and one anti-ssDNA </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> five scFv showed the same antigen binding properties as the original mAb </plain></SENT>
<SENT sid="3" pm="."><plain>Replacement of the pathogenic CAM V(H) domain with the non-pathogenic CAL V(H) or anti-ssDNA V(H) decreased the binding affinity of the scFv to beta(2)GPI and completely abrogated the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity </plain></SENT>
<SENT sid="4" pm="."><plain>Exchanging the CAM V(H) with anti-DNA V(H) resulted in a shift from anti-beta(2)GPI to anti-ssDNA binding of the scFv </plain></SENT>
<SENT sid="5" pm="."><plain>Replacement of the CAM V(L) with CAL V(L) did not affect the binding and activity </plain></SENT>
<SENT sid="6" pm="."><plain>BALB/c mice were immunized with the anti-beta(2)GPI scFv, and the scFv resulting from the substitution of the heavy (H) and light (L) chains </plain></SENT>
<SENT sid="7" pm="."><plain>The mice which were immunized with CAM, 2C4C2 and CAR scFv developed clinical manifestations of experimental anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome </plain></SENT>
<SENT sid="8" pm="."><plain>Elevated titers of mouse anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL), anti-beta(2)GPI, associated with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0003645'>prolonged activated partial thromboplastin time</z:hpo> and a high percentage of <z:e sem="disease" ids="C0015951" disease_type="Disease or Syndrome" abbrv="">fetal resorptions</z:e> were detected, in the CAM scFv group and in the scFv composed of CAM V(H) groups </plain></SENT>
<SENT sid="9" pm="."><plain>High titers of aCL, anti-beta(2)GPI, anti-ss/dsDNA and anti-<z:chebi fb="0" ids="15358">histone</z:chebi> associated with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> findings were observed in the sera of the 2C4C2 scFv-immunized mice </plain></SENT>
<SENT sid="10" pm="."><plain>Immunization with CAL scFv did not lead to any clinical findings </plain></SENT>
<SENT sid="11" pm="."><plain>The current study shows that scFv of pathogenic antibodies are capable of inducing the same clinical manifestations as the whole antibody molecule upon active immunization </plain></SENT>
<SENT sid="12" pm="."><plain>Replacement of H/L chains point to the importance of the V(H) domains in the pathogenic potential of anti-beta(2)GPI </plain></SENT>
</text></document>